CN115397804A - 右美沙酮用于神经精神障碍和疾病的疾病改善治疗 - Google Patents

右美沙酮用于神经精神障碍和疾病的疾病改善治疗 Download PDF

Info

Publication number
CN115397804A
CN115397804A CN202080097944.9A CN202080097944A CN115397804A CN 115397804 A CN115397804 A CN 115397804A CN 202080097944 A CN202080097944 A CN 202080097944A CN 115397804 A CN115397804 A CN 115397804A
Authority
CN
China
Prior art keywords
disorder
dexmethadone
nmdar
composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080097944.9A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·L·曼佛雷蒂
查尔斯·E·因图里西
S·德马丁
A·马塔雷
J·斯格里尼亚尼
A·卡瓦利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Universita degli Studi di Padova
Original Assignee
Institute for Research in Biomedicine IRB
Universita degli Studi di Padova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB, Universita degli Studi di Padova filed Critical Institute for Research in Biomedicine IRB
Publication of CN115397804A publication Critical patent/CN115397804A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
CN202080097944.9A 2020-01-03 2020-12-30 右美沙酮用于神经精神障碍和疾病的疾病改善治疗 Pending CN115397804A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062956839P 2020-01-03 2020-01-03
US62/956,839 2020-01-03
US202062963874P 2020-01-21 2020-01-21
US62/963,874 2020-01-21
US202062993188P 2020-03-23 2020-03-23
US62/993,188 2020-03-23
US202063010391P 2020-04-15 2020-04-15
US63/010,391 2020-04-15
US202063031785P 2020-05-29 2020-05-29
US63/031,785 2020-05-29
PCT/US2020/067498 WO2021138443A1 (en) 2020-01-03 2020-12-30 Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases

Publications (1)

Publication Number Publication Date
CN115397804A true CN115397804A (zh) 2022-11-25

Family

ID=76687448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080097944.9A Pending CN115397804A (zh) 2020-01-03 2020-12-30 右美沙酮用于神经精神障碍和疾病的疾病改善治疗

Country Status (12)

Country Link
US (1) US20230017786A1 (https=)
EP (1) EP4085044A4 (https=)
JP (2) JP2023509484A (https=)
KR (1) KR20220164470A (https=)
CN (1) CN115397804A (https=)
AU (1) AU2020419181A1 (https=)
BR (1) BR112022013160A2 (https=)
CA (1) CA3166254A1 (https=)
MX (1) MX2022007768A (https=)
TW (1) TW202140415A (https=)
UY (1) UY39007A (https=)
WO (1) WO2021138443A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119202724A (zh) * 2024-09-25 2024-12-27 宁夏医科大学总医院 一种脓毒症心肌病诊断模型的构建方法及诊断系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US9468611B2 (en) * 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
EP2906202A4 (en) * 2012-10-15 2016-04-27 Isa Odidi ORAL DRUG RELIEF FORMULATIONS
AU2018215056A1 (en) * 2017-01-31 2019-08-08 Charles E. Inturrisi D-methadone and its derivatives for use in the treatment of disorders of the nervous system
CA3064846A1 (en) * 2017-05-25 2018-11-29 Glytech, Llc Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
EP3917619A4 (en) * 2019-01-30 2022-10-26 University of Padova Structurally modified opioids for prevention and treatment of diseases and conditions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119202724A (zh) * 2024-09-25 2024-12-27 宁夏医科大学总医院 一种脓毒症心肌病诊断模型的构建方法及诊断系统

Also Published As

Publication number Publication date
JP2023509484A (ja) 2023-03-08
US20230017786A1 (en) 2023-01-19
WO2021138443A1 (en) 2021-07-08
EP4085044A1 (en) 2022-11-09
MX2022007768A (es) 2022-09-27
BR112022013160A2 (pt) 2022-11-08
UY39007A (es) 2021-07-30
KR20220164470A (ko) 2022-12-13
EP4085044A4 (en) 2024-06-12
CA3166254A1 (en) 2021-07-08
JP2026062924A (ja) 2026-04-10
TW202140415A (zh) 2021-11-01
AU2020419181A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
Hayashi et al. An update on the development of drugs for neuropsychiatric disorders: focusing on the σ1 receptor ligand
Samuels et al. The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor
Brensilver et al. Pharmacotherapy of amphetamine‐type stimulant dependence: an update
Strong et al. NMDA receptor modulators: an updated patent review (2013–2014)
Wang et al. Dezocine exhibits antihypersensitivity activities in neuropathy through spinal μ-opioid receptor activation and norepinephrine reuptake inhibition
Jamesa et al. The insomnia-addiction positive feedback loop: role of the orexin system
Levinstein et al. Redefining ketamine pharmacology for antidepressant action: synergistic NMDA and opioid receptor interactions?
JP2018008981A (ja) パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
Braudeau et al. Chronic treatment with a promnesiant GABA‐A α5‐selective inverse agonist increases immediate early genes expression during memory processing in mice and rectifies their expression levels in a Down syndrome mouse model
JP2011511845A (ja) アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物
JP2026062924A (ja) 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン
US20070184490A1 (en) Neuronal nicotinic receptor ligands and their use
Berrocoso et al. Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression
Stancil et al. Developmental considerations for the use of naltrexone in children and adolescents
Blum et al. Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?
Banks Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder
Kyzer et al. Classics in chemical neuroscience: buprenorphine
Breault et al. Opioid analgesics: rise and fall of ligand biased signaling and future perspectives in the quest for the holy grail
Oulis et al. Bupropion-induced sleepwalking
Guan The role of trace amine-associated receptor 1 (TAAR1) in the pathophysiology and treatment of depression
KR20210126628A (ko) 질환 및 병태의 예방 및 치료를 위한 구조적으로 변형된 오피오이드
Głuch-Lutwin et al. β-ARRESTINS AS KEY SWITCHES IN GPCR SIGNALING: FROM MOLECULAR STRUCTURE TO CLINICAL IMPLICATIONS--A NARRATIVE REVIEW.
Siddiqui Cardiovascular Risk Factors Amongst Individuals with Schizophrenia Receiving General-Population Smoking Cessation Treatment: An Observational Study
Kimura Novel AMPA Receptor Potentiators TAK-137 and TAK-653 as Potential Rapid-Acting Antidepressants
Lékó et al. Approved, Promising, and Experimental

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination